ICCM Stock Analysis: Buy, Sell, or Hold?
ICCM - IceCure Medical Ltd. Ordinary Shares
$5.93
0.53 (9.81%)
▲
5d:
+148.12%
30d:
+2418.05%
90d:
+843.67%
WAIT
LOW Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When ICCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ICCM is 50.5% above its trading range ($3.94). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ICCM is 50.5% above its trading range ($3.94). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ICCM is currently trading at $5.93, which is considered extended relative to its 30-day fair value range of $-0.19 to $3.94. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.4) compared to its historical average (7.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ICCM is in a downtrend. The price is approaching resistance at $5.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.8% recently.
Market Sentiment: ICCM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.50 (+650.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ICCM is in a downtrend. The price is approaching resistance at $5.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.8% recently.
Market Sentiment: ICCM has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.50 (+650.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.19 -
$3.94
Company Quality Score
55/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
57.1%
All Signals
- BEARISH: Price significantly overextended (+50.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+9.8%)
- BULLISH: Trading 650.4% below Wall St target ($44.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 50.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$-0.19 -
$3.94
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.13
Resistance Level
$5.69
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.41
Wall Street Target
$44.50
(+650.4%)
Revenue Growth (YoY)
25.7%
PE vs Historical
-1.4 vs 7.5
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 2:22 AM ET
Data refreshes hourly during market hours. Next update: 3:22 AM
Data refreshes hourly during market hours. Next update: 3:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
